Comparative Pharmacology
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS versus LAMIVUDINE TENOFOVIR DISOPROXIL FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS versus LAMIVUDINE TENOFOVIR DISOPROXIL FUMARATE.
LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS vs LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase by competing with natural substrates and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing conformational disruption. Zidovudine is an NRTI that inhibits viral reverse transcriptase after intracellular phosphorylation to its active triphosphate form.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI); tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor (NtRTI). Both inhibit HIV-1 reverse transcriptase and hepatitis B virus polymerase, causing chain termination of viral DNA.
One tablet (150 mg lamivudine/200 mg nevirapine/300 mg zidovudine) orally twice daily.
One tablet (300 mg tenofovir disoproxil fumarate and 300 mg lamivudine) orally once daily.
None Documented
None Documented
Lamivudine: 5-7h (adults), prolonged in renal impairment. Nevirapine: 25-30h (single dose), 40-45h (multiple doses, autoinduction). Zidovudine: 0.5-3h (terminal), prolonged in hepatic impairment.
Lamivudine: 5-7 hours (healthy), up to 13.1 hours (moderate renal impairment). Tenofovir: 17-25 hours (HIV), 32-49 hours (hepatitis B), prolonged in renal impairment.
Lamivudine: ~70% renal (glomerular filtration and tubular secretion, unchanged). Nevirapine: ~80% biliary/fecal (metabolites), ~10% renal (unchanged). Zidovudine: ~75% renal (metabolism to glucuronide, tubular secretion).
Lamivudine: predominantly renal (~70% unchanged). Tenofovir: renal (~70-80% unchanged via glomerular filtration and active tubular secretion).
Category A/B
Category A/B
NRTI
NRTI